Glioblastoma Pipeline Analysis 2025 by DelveInsight | Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI

DelveInsight's, "Glioblastoma- Pipeline Insight, 2025" report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight's analysis shows that the Glioblastoma pipeline includes over 180 key companies actively developing more than 200 therapies for Glioblastoma treatment.

Glioblastoma Overview:

Glioblastoma Multiforme (GBM) is the most common and aggressive primary brain tumor in adults, representing over half of all primary brain tumors and about 20% of intracranial tumors. Despite improvements in diagnosis and treatment, the prognosis for GBM remains poor due to its complex genetic and molecular abnormalities, which disrupt key signaling pathways and drive tumor progression through somatic mutations.

GBM is highly invasive, infiltrating brain tissue along nerve fibers, blood vessels, and internal brain linings, making complete surgical removal nearly impossible. It most commonly develops in the subcortical regions of the cerebrum, including the temporal, parietal, frontal, and occipital lobes, but can also arise in deeper structures such as the thalamus, cerebellum, and, rarely, the brainstem or spinal cord.

Symptoms are often nonspecific and can include headaches, personality changes, nausea, seizures, cognitive decline, and focal neurological deficits. In some cases, patients may experience psychiatric or balance-related symptoms, such as vertigo. The tumor's aggressive growth and widespread infiltration contribute to its high lethality.

Download our report @ https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

"Glioblastoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Glioblastoma Therapeutics Market.

Key Takeaways from the Glioblastoma Pipeline Report

DelveInsight's Glioblastoma pipeline report highlights an active landscape, with over 180 companies developing more than 200 therapies for Glioblastoma treatment.

Recent regulatory developments include:

*
The FDA approved an Investigational Device Exemption (IDE) for Alpha DaRT, a novel alpha-radiation therapy, enabling a pilot study in patients with recurrent glioblastoma to assess its safety and feasibility.

*
The FDA noted that overall survival data from the GBM-AGILE study could support standard approval of paxalisib, a PI3K inhibitor, as a potential new treatment for glioblastoma, pending further review.

*
Vorasidenib (Voranigo) was approved for adults and pediatric patients aged 12 and older with Grade 2 astrocytoma or oligodendroglioma carrying susceptible IDH1 or IDH2 mutations, marking the first systemic therapy approved for this population.

Key companies advancing glioblastoma therapies include Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies, and others.

Notable pipeline candidates under development include Enzastaurin, Asunercept, Berubicin, Azeliragon, VXM01, MB-101, among others.

Glioblastoma Pipeline Analysis

The Glioblastoma pipeline insights report 2025, provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the Glioblastoma Market.

*
Categorizes Glioblastoma therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging Glioblastoma drugs under development based on:

*
Stage of development

*
Glioblastoma Route of administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
Glioblastoma Mechanism of action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
Glioblastoma Licensing agreements

*
Funding and investment activities supporting future Glioblastoma market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Glioblastoma Emerging Drugs

*
Enzastaurin: Denovo BioPharma

*
Asunercept: Apogenix

*
Berubicin: CNS Pharmaceuticals

*
Azeliragon: Cantex

*
VXM01: VAXIMM

*
MB-101: Mustang Bio

Glioblastoma Companies

More than 180 leading companies are actively developing therapies for Glioblastoma, with Denovo advancing a drug candidate to the Phase III stage, the most advanced in development.

DelveInsight's report covers around 200+ products under different phases of Glioblastoma clinical trials like

*
Glioblastoma Late stage Therapies (Phase III)

*
Glioblastoma Mid-stage Therapies (Phase II)

*
Glioblastoma Early-stage Therapies (Phase I)

*
Glioblastoma Pre-clinical and Glioblastoma Discovery stage Therapies

*
Glioblastoma Discontinued & Inactive Therapies

Glioblastoma pipeline report provides the Glioblastoma therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Glioblastoma Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Glioblastoma Therapies and Key Glioblastoma Companies: Glioblastoma Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Glioblastoma Pipeline Therapeutic Assessment

- Glioblastoma Assessment by Product Type

- Glioblastoma By Stage

- Glioblastoma Assessment by Route of Administration

- Glioblastoma Assessment by Molecule Type

Download Glioblastoma Sample report to know in detail about the Glioblastoma treatment market @ Glioblastoma Therapeutic Assessment [https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Glioblastoma Current Treatment Patterns

4. Glioblastoma - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Glioblastoma Late-Stage Products (Phase-III)

7. Glioblastoma Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Glioblastoma Discontinued Products

13. Glioblastoma Product Profiles

14. Glioblastoma Key Companies

15. Glioblastoma Key Products

16. Dormant and Discontinued Products

17. Glioblastoma Unmet Needs

18. Glioblastoma Future Perspectives

19. Glioblastoma Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Glioblastoma Pipeline Reports Offerings [https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glioblastoma-pipeline-analysis-2025-by-delveinsight-denovo-biopharma-cantex-pharmaceuticals-cns-pharmaceuticals-canbridge-pharmaceuticals-vaximm-inovio-pharmaceuticals-mustang-bio-bullfrog-ai]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.